459 related articles for article (PubMed ID: 24206418)
1. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
Grimaldi-Bensouda L; Guillemot D; Godeau B; Bénichou J; Lebrun-Frenay C; Papeix C; Labauge P; Berquin P; Penfornis A; Benhamou PY; Nicolino M; Simon A; Viallard JF; Costedoat-Chalumeau N; Courcoux MF; Pondarré C; Hilliquin P; Chatelus E; Foltz V; Guillaume S; Rossignol M; Abenhaim L;
J Intern Med; 2014 Apr; 275(4):398-408. PubMed ID: 24206418
[TBL] [Abstract][Full Text] [Related]
2. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.
Grimaldi-Bensouda L; Rossignol M; Koné-Paut I; Krivitzky A; Lebrun-Frenay C; Clet J; Brassat D; Papeix C; Nicolino M; Benhamou PY; Fain O; Costedoat-Chalumeau N; Courcoux MF; Viallard JF; Godeau B; Papo T; Vermersch P; Bourgault-Villada I; Breart G; Abenhaim L;
J Autoimmun; 2017 May; 79():84-90. PubMed ID: 28190705
[TBL] [Abstract][Full Text] [Related]
3. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.
Geier DA; Geier MR
Clin Rheumatol; 2015 Jul; 34(7):1225-31. PubMed ID: 25535199
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.
Mok CC; Ho LY; Fong LS; To CH
Ann Rheum Dis; 2013 May; 72(5):659-64. PubMed ID: 22589375
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
[TBL] [Abstract][Full Text] [Related]
6. CNS demyelination and quadrivalent HPV vaccination.
Sutton I; Lahoria R; Tan I; Clouston P; Barnett M
Mult Scler; 2009 Jan; 15(1):116-9. PubMed ID: 18805844
[TBL] [Abstract][Full Text] [Related]
7. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
Scheller NM; Svanström H; Pasternak B; Arnheim-Dahlström L; Sundström K; Fink K; Hviid A
JAMA; 2015 Jan; 313(1):54-61. PubMed ID: 25562266
[TBL] [Abstract][Full Text] [Related]
8. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.
Geier DA; Geier MR
Immunol Res; 2017 Feb; 65(1):46-54. PubMed ID: 27406735
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine.
Chao C; Klein NP; Velicer CM; Sy LS; Slezak JM; Takhar H; Ackerson B; Cheetham TC; Hansen J; Deosaransingh K; Emery M; Liaw KL; Jacobsen SJ
J Intern Med; 2012 Feb; 271(2):193-203. PubMed ID: 21973261
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus vaccination and the risk of autoimmune disorders: A systematic review and meta-analysis.
Jiang HY; Shi YD; Zhang X; Pan LY; Xie YR; Jiang CM; Deng M; Ruan B
Vaccine; 2019 May; 37(23):3031-3039. PubMed ID: 31036452
[TBL] [Abstract][Full Text] [Related]
11. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases.
Hviid A; Svanström H; Scheller NM; Grönlund O; Pasternak B; Arnheim-Dahlström L
J Intern Med; 2018 Feb; 283(2):154-165. PubMed ID: 29044769
[TBL] [Abstract][Full Text] [Related]
13. Quadrivalent HPV vaccination reactions--more hype than harm.
Douglas RJ
Aust Fam Physician; 2009 Mar; 38(3):139-42. PubMed ID: 19283255
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance.
Gold MS; McIntyre P
Sex Health; 2010 Sep; 7(3):320-4. PubMed ID: 20719221
[TBL] [Abstract][Full Text] [Related]
15. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
Pomfret TC; Gagnon JM; Gilchrist AT
J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
17. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
[TBL] [Abstract][Full Text] [Related]
18. Safety of quadrivalent human papillomavirus vaccine administered routinely to females.
Klein NP; Hansen J; Chao C; Velicer C; Emery M; Slezak J; Lewis N; Deosaransingh K; Sy L; Ackerson B; Cheetham TC; Liaw KL; Takhar H; Jacobsen SJ
Arch Pediatr Adolesc Med; 2012 Dec; 166(12):1140-8. PubMed ID: 23027469
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of the risk of autoimmune thyroiditis, Guillain-Barré syndrome, and inflammatory bowel disease following vaccination with AS04-adjuvanted human papillomavirus 16/18 vaccine.
Rosillon D; Willame C; Tavares Da Silva F; Guignard A; Caterina S; Welby S; Struyf F
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1159-1167. PubMed ID: 32583515
[TBL] [Abstract][Full Text] [Related]
20. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
